Table 1.
Univariate and multivariate analyses of clinicopathological characteristics and genetic alterations on overall survival.
| Variable | Modality | N (%) | Univariate | Multivariate | ||
|---|---|---|---|---|---|---|
| 5-y OS % | P-value | HR (95% CI) | P-value | |||
| Age (years) | <65 | 62 (56) | 9.3 | 0.604 | ||
| ≥65 | 49 (44) | 15.2 | ||||
| Sex | Male | 66 (59) | 5.0 | 0.104 | ||
| Female | 45 (41) | 24.0 | ||||
| Tumor size (mm) | <50 | 36 (32) | 0.0 | 0.258 | ||
| ≥50 | 75 (68) | 14.1 | ||||
| Pre-operative CEA (ng/ml) | <200 | 85 (77) | 13.8 | 0.338 | ||
| ≥200 | 26 (23) | 5.1 | ||||
| Primary tumor site | Right-sided | 34 (31) | 9.7 | 0.157 | ||
| Left-sided | 77 (69) | 13.0 | ||||
| Histopathological grade | G1, 2 | 78 (70) | 14.2 | 0.001 | 1.00 | |
| G3 | 33 (30) | 6.7 | 1.30 (1.01–1.68) | 0.041 | ||
| T category | T2, 3 | 47 (42) | 0.0 | 0.059 | ||
| T4 | 64 (58) | 10.4 | ||||
| N category | N0 | 15 (14) | 24.1 | 0.036 | ||
| N1 | 96 (86) | 9.6 | ||||
| M category | M1a | 56 (50) | 15.6 | 0.511 | ||
| M1b | 55 (50) | 9.8 | ||||
| Liver metastasis | Absent | 23 (21) | 21.8 | 0.139 | ||
| Present | 88 (79) | 8.7 | ||||
| Lung metastasis | Absent | 77 (69) | 11.8 | 0.824 | ||
| Present | 34 (31) | 12.2 | ||||
| Peritoneal metastasis | Absent | 89 (80) | 13.5 | 0.116 | ||
| Present | 22 (20) | 5.5 | ||||
| Liver-limited metastasis | Absent | 64 (58) | 11.9 | 0.815 | ||
| Present | 47 (42) | 11.6 | ||||
| Number pf metastatic sites | 1 | 64 (58) | 16.0 | 0.753 | ||
| ≥2 | 47 (42) | 8.7 | ||||
| Residual tumor | R0 | 45 (41) | 19.2 | <0.001 | 0.54 (0.33–0.88) | 0.013 |
| R2 | 66 (59) | 6.5 | 1.00 | |||
| APC | Wild-type | 19 (17) | 19.1 | 0.399 | ||
| Mutant | 92 (83) | 9.5 | ||||
| ARID1A | Wild-type | 96 (86) | 11.7 | 0.725 | ||
| Mutant | 15 (14) | 16.1 | ||||
| ATM | Wild-type | 99 (89) | 11.4 | 0.676 | ||
| Mutant | 12 (11) | 11.1 | ||||
| BRAF | Wild-type | 98 (88) | 12.7 | <0.001 | 1.00 | |
| Non-V600E | 6 (5) | 33.3 | 1.52 (0.54–4.30) | 0.424 | ||
| V600E | 7 (6) | 0.0 | 3.47 (1.45–8.29) | 0.005 | ||
| FBXW7 | Wild-type | 94 (85) | 9.3 | 0.603 | ||
| Mutant | 17 (15) | 25.7 | ||||
| KRAS | Wild-type | 72 (65) | 12.0 | 0.348 | ||
| Mutant | 39 (35) | 13.5 | ||||
| PIK3CA | Wild-type | 97 (87) | 12.8 | 0.082 | ||
| Mutant | 14 (13) | 0.0 | ||||
| PTEN | Wild-type | 71 (64) | 15.9 | 0.677 | ||
| Mutant | 40 (36) | 7.4 | ||||
| SMAD2 | Wild-type | 96 (86) | 12.9 | 0.288 | ||
| Mutant | 15 (14) | 6.7 | ||||
| SMAD4 | Wild-type | 73 (66) | 15.3 | 0.281 | ||
| Mutant | 38 (34) | 7.3 | ||||
| SRC | Wild-type | 97 (87) | 14.2 | 0.035 | 1.00 | |
| Mutant | 14 (13) | 0.0 | 1.99 (1.10–3.59) | 0.023 | ||
| TP53 | Wild-type | 26 (23) | 17.5 | 0.483 | ||
| Mutant | 85 (77) | 10.3 | ||||
Only genes altered in more than 10% of patients (n = 12) are noted in this table, but all 31 genes altered in more than 5% of patients were evaluated.
95% CI 95% confidence interval, HR hazard ratio, OS overall survival.